FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2002556051> ?p ?o ?g. }

• W2002556051 endingPage "e56306" @default.
• W2002556051 startingPage "e56306" @default.
• W2002556051 abstract "Relapse rates following current methamphetamine abuse treatments are very high (∼40–60%), and the neuropsychiatric impairments (e.g., cognitive deficits, mood disorders) that arise and persist during remission from methamphetamine addiction likely contribute to these high relapse rates. Pharmacotherapeutic development of medications to treat addiction has focused on neurotransmitter systems with only limited success, and there are no Food and Drug Administration approved pharmacotherapies for methamphetamine addiction. A growing literature shows that methamphetamine alters peripheral and central immune functions and that immune factors such as cytokines, chemokines, and adhesion molecules play a role in the development and persistence of methamphetamine induced neuronal injury and neuropsychiatric impairments. The objective of this study was to evaluate the efficacy of a new immunotherapy, partial MHC/neuroantigen peptide construct (RTL551; pI-Ab/mMOG-35-55), in treating learning and memory impairments induced by repeated methamphetamine exposure. C57BL/6J mice were exposed to two different methamphetamine treatment regimens (using repeated doses of 4 mg/kg or 10 mg/kg, s.c.). Cognitive performance was assessed using the Morris water maze and CNS cytokine levels were measured by multiplex assay. Immunotherapy with RTL551 improved the memory impairments induced by repeated methamphetamine exposure in both mouse models of chronic methamphetamine addiction. Treatment with RTL551 also attenuated the methamphetamine induced increases in hypothalamic interleukin-2 (IL-2) levels. Collectively, these initial results indicate that neuroimmune targeted therapies, and specifically RTL551, may have potential as treatments for methamphetamine-induced neuropsychiatric impairments." @default.
• W2002556051 created "2016-06-24" @default.
• W2002556051 creator A5004052621 @default.
• W2002556051 creator A5025520721 @default.
• W2002556051 creator A5056010266 @default.
• W2002556051 creator A5073950799 @default.
• W2002556051 date "2013-02-27" @default.
• W2002556051 modified "2023-10-16" @default.
• W2002556051 title "Partial MHC/Neuroantigen Peptide Constructs: A Potential Neuroimmune-Based Treatment for Methamphetamine Addiction" @default.
• W2002556051 cites W1511310252 @default.
• W2002556051 cites W1553398873 @default.
• W2002556051 cites W1557644371 @default.
• W2002556051 cites W1595671608 @default.
• W2002556051 cites W1941604713 @default.
• W2002556051 cites W1966388230 @default.
• W2002556051 cites W1976206947 @default.
• W2002556051 cites W1984107995 @default.
• W2002556051 cites W1992861430 @default.
• W2002556051 cites W1998736596 @default.
• W2002556051 cites W1999359671 @default.
• W2002556051 cites W2008867730 @default.
• W2002556051 cites W2009503318 @default.
• W2002556051 cites W2015653858 @default.
• W2002556051 cites W2018557397 @default.
• W2002556051 cites W2021338883 @default.
• W2002556051 cites W2022056804 @default.
• W2002556051 cites W2024977803 @default.
• W2002556051 cites W2029490192 @default.
• W2002556051 cites W2033658202 @default.
• W2002556051 cites W2037197326 @default.
• W2002556051 cites W2043790266 @default.
• W2002556051 cites W2048020456 @default.
• W2002556051 cites W2049679215 @default.
• W2002556051 cites W2050431379 @default.
• W2002556051 cites W2054590164 @default.
• W2002556051 cites W2055284738 @default.
• W2002556051 cites W2055500305 @default.
• W2002556051 cites W2063273989 @default.
• W2002556051 cites W2063934960 @default.
• W2002556051 cites W2067336684 @default.
• W2002556051 cites W2068311250 @default.
• W2002556051 cites W2074190898 @default.
• W2002556051 cites W2083131011 @default.
• W2002556051 cites W2085864665 @default.
• W2002556051 cites W2087374400 @default.
• W2002556051 cites W2088922863 @default.
• W2002556051 cites W2089082039 @default.
• W2002556051 cites W2091778197 @default.
• W2002556051 cites W2097871984 @default.
• W2002556051 cites W2098139332 @default.
• W2002556051 cites W2101953179 @default.
• W2002556051 cites W2111776730 @default.
• W2002556051 cites W2116477105 @default.
• W2002556051 cites W2126939740 @default.
• W2002556051 cites W2135980918 @default.
• W2002556051 cites W2140906352 @default.
• W2002556051 cites W2141405812 @default.
• W2002556051 cites W2142145561 @default.
• W2002556051 cites W2144534798 @default.
• W2002556051 cites W2145948876 @default.
• W2002556051 cites W2156379444 @default.
• W2002556051 cites W2160588949 @default.
• W2002556051 cites W2160954639 @default.
• W2002556051 cites W2161516646 @default.
• W2002556051 cites W2162097818 @default.
• W2002556051 cites W2163407153 @default.
• W2002556051 cites W2172164520 @default.
• W2002556051 doi "https://doi.org/10.1371/journal.pone.0056306" @default.
• W2002556051 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3584080" @default.
• W2002556051 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23460798" @default.
• W2002556051 hasPublicationYear "2013" @default.
• W2002556051 type Work @default.
• W2002556051 sameAs 2002556051 @default.
• W2002556051 citedByCount "13" @default.
• W2002556051 countsByYear W20025560512013 @default.
• W2002556051 countsByYear W20025560512014 @default.
• W2002556051 countsByYear W20025560512015 @default.
• W2002556051 countsByYear W20025560512016 @default.
• W2002556051 countsByYear W20025560512017 @default.
• W2002556051 countsByYear W20025560512019 @default.
• W2002556051 countsByYear W20025560512020 @default.
• W2002556051 countsByYear W20025560512021 @default.
• W2002556051 countsByYear W20025560512023 @default.
• W2002556051 crossrefType "journal-article" @default.
• W2002556051 hasAuthorship W2002556051A5004052621 @default.
• W2002556051 hasAuthorship W2002556051A5025520721 @default.
• W2002556051 hasAuthorship W2002556051A5056010266 @default.
• W2002556051 hasAuthorship W2002556051A5073950799 @default.
• W2002556051 hasBestOaLocation W20025560511 @default.
• W2002556051 hasConcept C118552586 @default.
• W2002556051 hasConcept C15744967 @default.
• W2002556051 hasConcept C166940927 @default.
• W2002556051 hasConcept C178790620 @default.
• W2002556051 hasConcept C185592680 @default.
• W2002556051 hasConcept C2779989194 @default.
• W2002556051 hasConcept C2780114369 @default.
• W2002556051 hasConcept C2780376393 @default.
• W2002556051 hasConcept C48856860 @default.

• next